Geron Corporation — FY2012 Form 10-K
Reporting period: Fiscal year ended December 31, 2012; filed March 15, 2013. Geron was a clinical-stage biopharmaceutical company with no marketed therapeutic products. Its principal development candidate was imetelstat, a telomerase inhibitor.
Financial results and liquidity
| Metric | FY2012 | FY2011 |
|---|---|---|
| Revenue | $2.7 million | $2.4 million |
| Research and development expense | $51.4 million | $69.3 million |
| Total operating expenses | $74.5 million | $98.6 million |
| Operating loss | $71.8 million | $96.1 million |
| Net loss | $68.9 million | $96.9 million |
| Basic and diluted loss per share | $0.54 | $0.78 |
| Net cash used in operating activities | $55.1 million | $62.4 million |
Revenue remained minimal and came primarily from license fees and royalties, not therapeutic product sales. Lower R&D costs—mainly following the stem-cell program shutdown and timing of imetelstat manufacturing—contributed to reduced operating and net losses. FY2012 included $2.7 million of restructuring charges; FY2011 included $5.4 million.
Fourth quarter 2012: Revenue was $689,000, operating expenses were $19.2 million, net loss was $15.9 million, and loss per share was $0.12. Fourth-quarter operating expenses included the $2.7 million restructuring charge.
Year-end liquidity: Cash, restricted cash, cash equivalents and marketable securities totaled $96.3 million, down from $154.2 million a year earlier. Working capital was $84.3 million; current assets were $98.4 million and current liabilities $14.1 million. Geron reported no outstanding debt at year-end. Accumulated deficit was $854.4 million. Management estimated existing resources, equipment financing availability and interest income would fund the then-current operating level for at least 12 months; future capital needs remained substantial.
Operating cash use was partly offset by $61.0 million of net investing cash inflow, principally marketable-security maturities. Financing activities provided $150,000. The company had an unused at-the-market facility permitting up to $50 million of stock sales, and an effective shelf registration statement for offerings up to $200 million.
Business developments and comparison with prior period
- Geron narrowed its focus to imetelstat after discontinuing GRN1005 in December 2012. It reduced its workforce from 107 positions to 64 full-time employees; further restructuring costs and cash payments were expected in 2013.
- In the Phase 2 essential thrombocythemia trial, the first 14 patients had platelet-count reductions; 13 of 14 achieved normalized platelet counts. JAK2 V617F allele burden declined in all seven patients with that mutation, with partial molecular responses in six. These were early, single-arm results, not evidence of approval or confirmed benefit in other diseases.
- An investigator-sponsored Mayo Clinic trial began evaluating imetelstat in myelofibrosis, with enrollment planned for up to 29 patients. Geron was considering further development in myelofibrosis and other myeloid malignancies, subject to trial results.
- The multiple myeloma study was no longer enrolling. Preliminary biomarker results showed a decline in detected progenitor cells in eight of nine assessed patients, while eight of ten patients experienced Grade 3–4 thrombocytopenia and neutropenia.
- The metastatic breast cancer trial was stopped after progression-free survival was shorter in the imetelstat arm than in the comparator arm. In NSCLC, an interim analysis showed median progression-free survival of 2.8 months with imetelstat versus 2.6 months with observation. An initially favorable exploratory short-telomere subgroup finding was not reproduced in a March 2013 updated analysis using more mature follow-up and a refined assay.
- In January 2013, Geron agreed to contribute its discontinued stem-cell and autologous immunotherapy assets to BioTime Acquisition Corporation (BAC). At closing, Geron was to receive approximately 6.54 million BAC Series A shares for pro rata distribution to its stockholders, plus potential royalties. Closing was conditional and expected by September 30, 2013; it had not closed as of the filing.
Outlook, risks and unusual items
Management expected R&D expense to decline in 2013 as the company focused on imetelstat and ended GRN1005 development. It did not provide revenue or earnings guidance and stated it could not reliably estimate the time or investment required to commercialize imetelstat. The company expected continued losses and no therapeutic-product revenue for years, if ever.
- Geron depended principally on one early-stage candidate; clinical efficacy, regulatory approval and commercial success were uncertain. Imetelstat’s observed risks included cytopenias and abnormal liver-function tests.
- Manufacturing scale, cost and quality were uncertain. Geron relied on third-party manufacturers and clinical vendors, without long-term supply commitments.
- Cash was declining; additional financing might be needed, potentially on dilutive or unfavorable terms. The company had incurred losses every year since inception.
- Patent rights, third-party licenses, competition and the completion of the BAC asset transfer presented material uncertainties. The BAC transaction also carried conditions and potential indemnification obligations.
- Unusual FY2012 items included a $2.5 million non-refundable payment for assignment of telomerase-activation technology and the $2.7 million restructuring charge. Geron also terminated the Asia Biotech royalty arrangement.
The independent auditor issued an unqualified opinion on the financial statements and internal controls; management and the auditor reported effective internal control over financial reporting as of December 31, 2012.
Most important facts for investors to verify
- Subsequent clinical data, safety findings and trial progress for imetelstat, particularly in myelofibrosis; confirm the limitations of the small, early ET results.
- Cash burn, remaining runway and any new financing or share issuance, including use of the ATM or shelf registration.
- Progress, costs and final terms of the BAC transaction, including closing conditions, distribution mechanics and potential royalties.
- Whether the NSCLC subgroup hypothesis and telomere-length assay can be validated; the updated analysis did not reproduce the earlier treatment effect.
- Manufacturing feasibility and cost, continued supply availability, and material liver or blood-cell toxicities as trials advance.